Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974003 | 0.94 | KDM4E (0.33) | BRD4BRD2CA2CHKAKDM4E | |
| SCHEMBL27755656 | 0.88 | BRD4 (0.35) | BRD4BRD2LMNA | |
| SCHEMBL442676 | 0.81 | BRD4 (0.44) | BRD4BRD2LMNAPIK3CDTSHR | |
| SCHEMBL2997559 | 0.79 | BRD4 (0.42) | BRD4BRD2LMNAPIK3CDTSHR | |
| SCHEMBL27670203 | 0.79 | TPMT (0.42) | — | |
| SCHEMBL27762482 | 0.78 | BRD4 (0.34) | BRD4BRD2 | |
| SCHEMBL15168977 | 0.77 | BRD4 (0.41) | BRD4BRD2LMNAPIK3CDTSHR | |
| SCHEMBL28478099 | 0.77 | — | — | |
| SCHEMBL10525669 | 0.77 | BRD4 (0.39) | BRD4BRD2LMNAPIK3CDTSHR | |
| SCHEMBL28494512 | 0.76 | SLC6A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288010-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-09-15 | — | — | US | claimed |
| EP-4034116-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2021062232-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-04-01 | — | — | WO | claimed |
| US-20220288010-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4034116-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021062232-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2016127358-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| CN-102093285-B | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL | 2013-10-16 | — | — | CN | disclosed |
| CN-1989104-B | Cyclic amide derivatives, their preparation and their use as antithrombotic agents | TAKEDA PHARMACEUTICAL | 2011-07-13 | — | — | CN | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
| CN-1989104-A | Cyclic amide derivatives, their preparation and their use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2007-06-27 | — | — | CN | disclosed |
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1748985-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
| WO-2005113504-A1 | CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-01 | — | — | WO | disclosed |
| CN-1101310-C | Highly asymmetric, hydrophilic, microfiltration membranes having large pore | USF FILTRATION & SEPARATIONS (US) | 2003-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | BRD4 623/4885BRD2 408/4885LMNA 2702/4885 |
| US-20220288010-A1 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | MGLL, OPRL1, PNLIP | BRD4 745/4885BRD2 1861/4885LMNA 4410/4885 |
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | BRD4 110/4885BRD2 95/4885LMNA 1557/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | BRD4 544/4885BRD2 342/4885LMNA 2679/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | BRD4 623/4885BRD2 408/4885LMNA 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.